2,220 reports of this reaction
1.9% of all LETROZOLE TABLETS reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for LETROZOLE TABLETS, manufactured by Avet Pharmaceuticals Inc.. There are 2,220 FDA adverse event reports linking LETROZOLE TABLETS to ASTHENIA. This represents approximately 1.9% of all 116,600 adverse event reports for this drug.
Patients taking LETROZOLE TABLETS who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for LETROZOLE TABLETS, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for LETROZOLE TABLETS:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 2,220 FDA reports for LETROZOLE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.9% of all adverse event reports for LETROZOLE TABLETS, making it a notable side effect.
If you experience asthenia while taking LETROZOLE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.